Confident of Market Turnaround, MDS Proteomics Plans IPO for 2002

Dec 17, 2001

Premium

MDS Proteomics plans to go through with an initial public offering next year to acquire additional funding, the company’s new CFO said last week.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Breaking News

The Scan

Try the Other Version

Researchers find that a personalized medicine approach could help people who experience pain while taking statins, New Scientist reports.

You Do Your Way

US National Science Foundation is continuing its responsible research conduct training policy despite its flaws, ScienceInsider reports.

CRISPR Discussions

A CRISPR-themed meeting explored how the tool could and should be used, Wired reports.

This Week in Science

In Science this week: database of proteins' effects on cancer, targeted error correction sequencing, and more.

Featured White Papers

Lipid Removal With Reference Applications in Serum and Bile Proteomics

Albumin & IgG Removal Reference Applications

95-plex Immune Cell Phenotyping Assay

Oct

10

Featured Webinar

GenomeWeb/ABRF 2017 Webinar Series: Ask the Experts: Ensuring High-Quality Proteomic Studies with Core Lab Resources

This online, interactive seminar will answer researchers’ most pressing questions about how to gain outstanding research results from proteomic studies.

Main menu